Rappaport Connects Gateway |
Follow Us |
Fellow_MGH_Headshot_Tsai_Guochuan_ E_ Tsai, MD PhD

Guochuan Tsai

Fellow_MGH_Headshot_Tsai_Guochuan_ E_ Tsai, MD PhD

Guochuan Tsai


Massachusetts General Hospital


MGH Research Fellows




Interview: Guochuan Emil Tsai, MD MAS – Founder & CEO, SyneuRx, Taiwan

For nearly 30 years, the funding provided by the Rappaport Foundation to physicians and researchers has allowed brilliance to flourish and breakthroughs to triumph in the areas of neurologic diseases and mental illness.

Dr. Tsai’s research has been focusing on developing novel treatments for CNS disorders. He and his group have successfully identified several new drug targets that will improve the symptoms and quality of life of people with mental illness. The treatment is based upon the N-methyl-D-aspartate (NMDA) receptor mechanism. He had shown that the NMDA therapeutics worked for populations refractory to the available treatments based upon our proof the principle studies at both the bench and bedside. It is not surprising that the novel therapeutics can benefit conditions including schizophrenia, depression, obsessive compulsive disorder, attention deficit hyperactivity disorder, mild cognitive impairment, Parkinson and dementia, for the NMDA receptor mechanism is the main regulatory mechanism of memory and cognition of brain function.